The Value of MiR-383, an Intronic MiRNA, as a Diagnostic and Prognostic Biomarker in Intestinal-Type Gastric Cancer
The Value of MiR-383, an Intronic MiRNA, as a Diagnostic and Prognostic Biomarker in Intestinal-Type Gastric Cancer
复制标题
DOI：
10.1007/s10528-017-9793-x
复制
发表时间：
2017-06-01
影响因子：
2.4
通讯作者：
Fateh, Alavieh
中科院分区：
文献类型：
--
作者：
Azarbarzin, Shirin;Feizi, Mohammad Ali Hosseinpour;Fateh, Alavieh
MicroRNA是一类基因表达调控非编码RNA，参与生命癌症之一的胃癌的发病机制。由于 miR-383 在某些类型的人类癌症中存在异常表达，因此在癌症治疗和诊断方面具有研究价值。 MiR-383 位于蛋白质编码基因 SGCZ 的内含子中，该基因在多种疾病中会出现失调。本研究的目的是探讨miR-383对肠型胃腺癌肿瘤发生的贡献。内镜检查期间，通过 qRT-PCR 检测 40 例胃癌患者的肿瘤组织和癌旁无瘤组织中 miR-383 的表达水平。此外，还确定了 miR-383 作为肿瘤标志物的敏感性及其异常表达与临床病理特征之间的关系。 qRT-PCR 数据显示 miR-383 在胃肿瘤发生过程中失调。与邻近的无肿瘤组织相比，MiR-383 在肠型胃腺癌中显着下调七倍（P < 0.001）。 miR-383 的错误调节并未揭示与临床特征的显着相关性。 ROC 面积为 80%，灵敏度为 76%，特异性为 84%，P < 0.001。目前的研究表明 miR-383 在肠型胃腺癌中下调。 miR-383 的下调可能被用作诊断胃癌的潜在肿瘤标志物，或者可能成为基因治疗的潜在靶点。
MicroRNAs, a class of gene expression regulatory non-coding RNAs, participate in the pathogenic mechanisms of gastric cancer which is one of the life-treating cancers. Due to its aberrant expression in some types of human cancer, miR-383 has the value of being investigated in relation to cancer treatment and diagnosis. MiR-383 is placed in intron of SGCZ, a protein-coding gene, which is subject to dysregulation in various diseases. The purpose of the current study was to investigate the contribution of miR-383 to intestinal-type gastric adenocarcinoma tumorigenesis. The expression level of miR-383 was investigated by qRT-PCR in pairs of tumorous and adjacent tumor-free tissues of 40 patients with gastric cancer during endoscopy. Also, the susceptibility of miR-383 as a tumor marker and the relationship between its aberrant expression and clinicopathological features were determined. qRT-PCR data showed that miR-383 was dysregulated during gastric tumorigenesis. MiR-383 was dramatically downregulated up to sevenfold in intestinal-type gastric adenocarcinoma compared with adjacent tumor-free tissues (P < 0.001). Misregulation of miR-383 did not reveal a significant correlation with clinical characteristics. The ROC area of 80% with 76% sensitivity and 84% specificity was determined by P < 0.001. The current study demonstrated downregulation of miR-383 in intestinal-type gastric adenocarcinoma. Downregulation of miR-383 might be used as a potential tumor marker for the diagnosis of gastric cancer or could be a potential target for gene therapy.